Fierce Biotech18h
BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific
BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...
BioSpace17h
BioNTech’s Bispecific Elicits Treatment Response in Majority of SCLC Patients
BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.
Endpoints News18h
BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer
BioNTech's BNT327 shows promising survival data in lung cancer trial, with 72.7% of patients surviving one year, ...
New PET radiotracer provides first look at inflammation biomarker in human brain
A novel PET imaging approach can effectively quantify a key enzyme associated with brain inflammation, according to research published in the March issue of The Journal of Nuclear Medicine. The ...